Corbus Pharmaceuticals Holdings (CRBP) Total Non-Current Liabilities (2016 - 2024)

Corbus Pharmaceuticals Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $13.5 million for Q4 2024.

• In Q4 2024, Total Non-Current Liabilities fell 61.71% year-over-year to $13.5 million; the TTM figure through Dec 2024 stood at $13.5 million (down 61.71% YoY), while the FY2024 annual figure was $13.5 million, down 61.71% from the prior year.
• Total Non-Current Liabilities was $13.5 million for Q4 2024 at Corbus Pharmaceuticals Holdings, down from $13.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.0 million in Q4 2020 to a low of $13.5 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $34.2 million across 5 years, with a median of $34.2 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities climbed 12.76% in 2023, then sank 61.94% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $57.0 million in 2020, then tumbled by 32.3% to $38.6 million in 2021, then dropped by 13.73% to $33.3 million in 2022, then rose by 5.51% to $35.1 million in 2023, then plunged by 61.71% to $13.5 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $13.5 million (Q4 2024), $13.7 million (Q3 2024), and $26.4 million (Q2 2024), per Business Quant data.